| Newport Beach, California--(Newsfile Corp. - March 24, 2020) -
Vivera Pharmaceuticals, Inc., a California based pharmaceutical company,
and the Coushatta Tribe of Louisiana today announce a new relationship
in the fight against COVID-19.
Anticipating a substantial increase in United States cases of COVID-19,
the two are working together to gain FDA emergency approval for
the Vivera Pharmaceuticals powered by Pharmact AG CoV-2 Rapid Test,
a novel rapid testing kit manufactured by Pharmact AG, a leading
German manufacturer of rapid diagnostic testing kits.
As States around the country issue mandatory stay-at-home orders,
and with no definitive end in sight to this global crisis, there
will be a significant increase in the need for reliable testing
to adequately serve those who need the most support. The CoV-2 Rapid
Test provides results at 20 minutes, making it ideal for point of
care testing and triage of large patient populations. This proprietary
assay does not require additional equipment or use of already overburdened
Both groups firmly believe that addressing this pandemic requires
decisive action on a national scale. Every part of the county has
been deeply affected, with millions of Americans, and the communities
they support, in need of immediate solutions.
"Vivera's focus on patient health is why we look forward to
working closely with the Coushatta Tribe of Louisiana. Vivera is
here to support Tribal leaders and their efforts in ensuring healthcare
for not only their people, but those across the country that are
affected. As more cases of community infections develop, healthcare
providers need to stay ahead of the diagnostic curve," stated
Paul Edalat, CEO of Vivera Pharmaceuticals.
"As the First People of this land we carry the genetic memory
of the devastation pandemics cause, but in this present moment of
crisis we are one tribe," said David Sickey, Tribal Chairman
of the Coushatta Tribe of Louisiana. "COVID-19 does not discriminate.
The virus doesn't care what ethnicity we are or what our political
ideology is. We are facing an invisible enemy that we must unite
to defeat. The CoV-2 Rapid Test brings visibility to this faceless
foe so that our heroes on the frontlines, the doctors, nurses and
first responders, know where to take the fight and how to treat
our fellow citizens who have contracted the virus. Fear is stoked
by the unknown. With these tests we can reduce the fear factor for
people across the United States."
Vivera and the Coushatta Tribe of Louisiana expect to begin offering
the Rapid Test as early as this week under the temporary approval
mechanisms set forth by the FDA for Emergency Use Authorization
For more information regarding the Vivera Pharmaceuticals powered
by Pharmact AG CoV-2 Rapid Test, and ordering information for healthcare
providers, please visit viverapharma.com.
the Coushatta Tribe of Louisiana
After many years and hardships, including being illegally "terminated"
without legislation during the Eisenhower administration, the Coushatta
Tribe was officially re-recognized by the United States Government
in 1973 and marked a major turning point in tribal history in 1985
with the election by popular vote of the first Coushatta tribal
From their earliest days as a proud, hard-working people struggling
to maintain long-standing traditions in the face of possible relocation,
the Coushatta Indians have endured and overcome every hardship they
have faced and have remained on tribal lands in and around Elton,
Louisiana, since the 1800s. Despite serious setbacks and some population
dispersal, the tribe's character and ideals have not only held fast,
but have been strengthened. The Coushatta language, Koasati, is
still spoken as a first language in the Coushatta community today.
The Coushatta Tribe of Louisiana owns and operates Coushatta Casino
Resort, which employs more than 2,400 area residents. For more information
about the Tribe, visit www.koasatiheritage.org.
For more information about the Coushatta Casino Resort, visit www.coushattacasinoresort.com
About Vivera Pharmaceuticals, Inc.
Vivera Pharmaceuticals, Inc. is an innovative, science-driven pharmaceutical
company focused on novel therapies for a variety of indications.
In addition to its pharmaceutical and medical device products,
the company has global exclusivity to license the patented and patent-pending
TABMELT® sublingual drug-delivery system for the pharmaceutical
use of therapeutic compounds. The company is vertically integrated
with patented technology, manufacturing capabilities, and distribution
for its products.
For more information, visit https://viverapharmaceuticals.com.
Investor Relations Inquiries:
Patrick Piette, CFA for Vivera Pharmaceuticals, Inc.
Karin Elz, for Vivera Pharmaceuticals, Inc.